
Last updated: 2026-09-16 13:20:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Theravance Biopharma, Inc. (TBPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.05, with a market capitalisation of $884.18M and a P/E ratio of 16.44. Over the past 52 weeks, its price has ranged from $13.08 to $21.03. This page covers its latest market performance, valuation, price trends and company information.
$884.18M | |
$17.05 | |
$43.44 | |
$6.10 | |
$17.04 | |
4.00 | |
645.11K | |
16.44 | |
$21.03 | |
$13.08 | |
-- | |
-- |
Theravance Biopharma, Inc. (TBPH) is trading at $17.05 in pre-market trading as of 2026-09-16 12:01:00, up 0.03% ($0.01) from the previous close of $17.04
Pre-market trading shows how investors are pricing TBPH before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Theravance Biopharma, Inc. (TBPH) moved from $17.08 to $17.05, representing a decline of 0.20% ($0.03).
The stock traded between $17.00 and $17.26 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 297.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 49.9%
TBPH is currently trading at $17.05, placing it 49.9% of the way from its 52-week low of $13.08 to its 52-week high of $21.03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 90 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Theravance Biopharma, Inc. (TBPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.